Acta Pharmaceutica, Vol. 72 No. 2, 2022.
Preliminary communication
https://doi.org/10.2478/acph-2022-0020
Promising inhibitors against main protease of SARS CoV-2 from medicinal plants: In silico identification
OLUWAKEMI EBENEZER
orcid.org/0000-0003-1054-9665
; Faculty of Natural Science, Department of Chemistry, Mangosuthu University of Technology, 511 Mangosuthu Highway, Durban, 4000, South Africa
MICHAEL SHAPI
; Faculty of Natural Science, Department of Chemistry, Mangosuthu University of Technology, 511 Mangosuthu Highway, Durban, 4000, South Africa
Abstract
Some compounds reported as active against SARS CoV were selected, and docking studies were performed using the main protease of SARS CoV-2 as the receptor. The docked complex analysis shows that the ligands selectively bind with the target residues and binding affinity of amentoflavone (‒10.1 kcal mol‒1), isotheaflavin-3'-gallate (‒9.8 kcal mol‒1), tomentin A and D (‒8.0 and ‒8.8 kcal mol‒1), theaflavin-3,3'-digallate (‒8.6 kcal mol‒1), papyriflavonol A (‒8.4 kcal mol‒1), iguesterin (‒8.0
kcal mol‒1) and savinin (‒8.3 kcal mol‒1) were ranked above the binding affinity of the reference, co-crystal ligand, ML188, a furan-2-carboxamide-based compound. To pinpoint the drug-like compound among the top-ranked compounds, the Lipinski’s rule of five and pharmacokinetic properties of all the selected compounds were evaluated. The results detailed that savinin exhibits high gastrointestinal absorption and can penetrate through the blood-brain barrier. Also, modifying these natural scaffolds with excellent binding affinity as new anti-SARS CoV agents may lead to discovering novel drug-like candidates with promising safety profiles.
Keywords
SARS CoV-2 main protease inhibitors; medicinal plants; molecular docking; ADMET properties
Hrčak ID:
262295
URI
Publication date:
30.6.2022.
Visits: 1.075 *